Both records in the supplied collection are traditional 510(k) submissions filed by Siemens Healthineers AG with a Forchheim, Germany address, and both received a Substantially Equivalent decision. The two clearances fall within weeks of each other in late 2026 and cover different device types: a hardware imaging system and a software platform. The collection contains no premarket approval or De Novo records, and the two entries are a snapshot of supplied filings rather than a measure of the company's total portfolio. [1][2]
MAGNETOM Free.XL clearance
MAGNETOM Free.XL was cleared under K262011 on November 5, 2026, with the submission received June 15, 2026. The FDA record lists the applicant as Siemens Healthineers AG, product code LNH, regulation number 892.1000, device class 2, advisory committee Radiology, and a Summary as the statement or summary type. The clearance type is Traditional and the third-party flag is N. [1]
Siemens Healthineers' own product pages describe MAGNETOM Free.XL as a 0.55 T MR system with a bore described as the world's first above 100 cm, XL gradients, helium-free DryCool Technology, and Deep Resolve for workflow and scan speed. The company frames it for interventional radiology demands. One company page carries a notice that the product is pending 510(k) clearance and not available for sale in the United States, and a November 30, 2025 press release is marked not for publication in the U.S. [4][6][8]
Syngo Carbon Space (VA4) clearance
Syngo Carbon Space (VA4) was cleared under K263048 on September 29, 2026, with the submission received August 31, 2026. The FDA record lists product code LLZ, regulation number 892.2050, device class 2, advisory committee Radiology, a Traditional clearance type, and a third-party flag of Y. The FDA clearance letter identifies the regulation as medical image management and processing system, Class II, and addresses correspondence to Siemens Healthineers AG care of a regulatory services firm in Saint Paul, Minnesota. [2][3]
The letter states that a risk analysis was completed and risk controls implemented for identified hazards, and that verification and validation testing met acceptance criteria to support the substantial equivalence claims. The record does not describe specific software functions, intended clinical uses beyond the regulation, or interoperability claims. [3]
Applicant identity and registration footprint
The FDA legal applicant on both records is Siemens Healthineers AG, with a Forchheim address in the filing data. A separate FDA establishment registration search returns seven results for the Siemens Healthineers name; the supplied excerpts show the result count and interface but not the individual establishment names or registration numbers, so the specific registered sites remain unknown. [1][2][7][9]
A company press release describes Siemens Healthineers as employing approximately 74,000 people worldwide and generating revenue of around €23.4 billion in fiscal 2025, which ended September 30, 2025. That description comes from the publisher and is not an FDA finding. [8]
What the filings do and do not establish
The collection contains two 510(k) records, both with a Substantially Equivalent decision, and no recall entries. That is a description of the supplied filings as of the snapshot date, not a statement about total company sales, total cleared portfolio, or safety performance. Neither record supplies clinical outcome data, and the company pages describe product features rather than cleared indications. [1][2]
